These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 12759518)
1. Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method. Fenyvesi T; Jörg I; Harenberg J Pathophysiol Haemost Thromb; 2002; 32(4):174-9. PubMed ID: 12759518 [TBL] [Abstract][Full Text] [Related]
2. Monitoring of anticoagulant effects of direct thrombin inhibitors. Fenyvesi T; Jörg I; Harenberg J Semin Thromb Hemost; 2002 Aug; 28(4):361-8. PubMed ID: 12244483 [TBL] [Abstract][Full Text] [Related]
3. Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time. Fenyvesi T; Jörg I; Weiss C; Harenberg J Thromb Res; 2003; 111(1-2):89-94. PubMed ID: 14644085 [TBL] [Abstract][Full Text] [Related]
4. Influence of lepirudin, argatroban, and melagatran on prothrombin time and additional effect of oral anticoagulation. Fenyvesi T; Joerg I; Harenberg J Clin Chem; 2002 Oct; 48(10):1791-4. PubMed ID: 12324500 [No Abstract] [Full Text] [Related]
5. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236 [TBL] [Abstract][Full Text] [Related]
6. Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial. Beiderlinden M; Werner P; Bahlmann A; Kemper J; Brezina T; Schäfer M; Görlinger K; Seidel H; Kienbaum P; Treschan TA BMC Anesthesiol; 2018 Feb; 18(1):18. PubMed ID: 29426286 [TBL] [Abstract][Full Text] [Related]
7. Effects of vitamin K antagonist phenprocoumon on activated partial thromboplastin time measurement of direct thrombin inhibitors. Fenyvesi T; Jörg I; Weiss C; Harenberg J Blood Coagul Fibrinolysis; 2004 Oct; 15(7):605-11. PubMed ID: 15389129 [TBL] [Abstract][Full Text] [Related]
8. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT Ann Pharmacother; 2004 Sep; 38(9):1383-8. PubMed ID: 15238620 [TBL] [Abstract][Full Text] [Related]
9. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma. Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786 [TBL] [Abstract][Full Text] [Related]
10. Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"? Seidel H; Kolde HJ Clin Appl Thromb Hemost; 2018 Mar; 24(2):287-294. PubMed ID: 28320219 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples. Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737 [TBL] [Abstract][Full Text] [Related]
12. Collaborative study on monitoring methods to determine direct thrombin inhibitors lepirudin and argatroban. Gray E; Harenberg J; J Thromb Haemost; 2005 Sep; 3(9):2096-7. PubMed ID: 16102117 [No Abstract] [Full Text] [Related]
13. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596 [TBL] [Abstract][Full Text] [Related]
14. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time. Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800 [TBL] [Abstract][Full Text] [Related]
15. In vitro effect of melagatran and lepirudin on clot-bound thrombin. Lebrazi J; Elalamy I; Samama MM Thromb Res; 2003 Jun; 110(4):249-52. PubMed ID: 14512090 [No Abstract] [Full Text] [Related]
16. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Dang CH; Durkalski VL; Nappi JM Pharmacotherapy; 2006 Apr; 26(4):461-8. PubMed ID: 16553503 [TBL] [Abstract][Full Text] [Related]
17. Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time. Koestenberger M; Cvirn G; Gallistl S; Muntean W Blood Coagul Fibrinolysis; 2004 Oct; 15(8):693-7. PubMed ID: 15613925 [TBL] [Abstract][Full Text] [Related]
18. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Elg M; Gustafsson D; Deinum J Thromb Haemost; 1997 Oct; 78(4):1286-92. PubMed ID: 9364999 [TBL] [Abstract][Full Text] [Related]
19. The effect of ex vivo anticoagulants on whole blood platelet aggregation. Kalb ML; Potura L; Scharbert G; Kozek-Langenecker SA Platelets; 2009 Feb; 20(1):7-11. PubMed ID: 19172515 [TBL] [Abstract][Full Text] [Related]
20. Recombinant human activated protein C, heparin and melagatran in umbilical cord versus adult plasma. Koestenberger M; Cvirn G; Gallistl S; Kutschera J; Muntean W Acta Paediatr; 2005 Jul; 94(7):884-9. PubMed ID: 16188810 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]